Eli Lilly partnership aims to identify new treatments for ALS based on antibodies from people with very slow disease ...

Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The collaboration agreement centres around Alchemab’s antibody discovery platform, ...

Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform. CAMBRIDGE, England, Jan. 9, 2025 /PRNewswire ...

The Big Pharma has inked a deal with British biotech Alchemab Therapeutics to develop new antibodies for ALS. Under the terms of the deal, Alchemab and Lilly will work together on up to five new ...

Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform. CAMBRIDGE, England, Jan. 9, 2025 /PRNewswire/ -- ...